Jivana Biotechnology raised $1 million for its preclinical work using targeted RNA-based therapies to treat a variety of cancers, according to a regulatory filing the Oak Park, Ill.-based company submitted this week.
The minimum investment from an outside investor was $50,000, the company reported, and it used an estimated $125,000 for payments to its executive officers. CEO Sidney Hopps filed the report, along with CFO Kenneth Templin.
Get the full story at our sister site, Drug Delivery Business News.
The post Jivana Biotechnology raises $1m for targeted cancer therapy appeared first on MassDevice.
from MassDevice http://ift.tt/2eMwc7i
Cap comentari:
Publica un comentari a l'entrada